cefixime 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antibiotics, cefalosporanic acid derivatives	537	79350-37-1

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: cefixime cefixim cefiximine cefixoral	A third-generation cephalosporin antibiotic that is stable to hydrolysis by beta-lactamases. Molecular weight: 453.44 Formula: C16H15N5O7S2 CLOGP: -0.17 LIPINSKI: 1 HAC: 12 HDO: 4 TPSA: 184.51 ALOGS: -3.64 ROTB: 8 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

cefixime
cefixim
cefiximine
cefixoral

A third-generation cephalosporin antibiotic that is stable to hydrolysis by beta-lactamases.

Molecular weight: 453.44
Formula: C16H15N5O7S2
CLOGP: -0.17
LIPINSKI: 1
HAC: 12
HDO: 4
TPSA: 184.51
ALOGS: -3.64
ROTB: 8

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.40	g	O

ADMET properties:

Show entries

Search:

Property	Value	Reference
BA (Bioavailability)	47 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
EoM (Fraction excreted unchanged in urine)	41 %	Benet LZ, Broccatelli F, Oprea TI
BDDCS (Biopharmaceutical Drug Disposition Classification System)	4	Benet LZ, Broccatelli F, Oprea TI
t_half (Half-life)	3.20 hours	Lombardo F, Berellini G, Obach RS
MRTD (Maximum Recommended Therapeutic Daily Dose)	29.33 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
CL (Clearance)	1 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.31 %	Lombardo F, Berellini G, Obach RS
Vd (Volume of distribution)	0.24 L/kg	Lombardo F, Berellini G, Obach RS
S (Water solubility)	0.10 mg/mL	Bocci G, Oprea TI, Benet LZ

Showing 1 to 9 of 9 entries

Previous1Next

Approvals:

Date	Agency	Company	Orphan
April 28, 1989	FDA

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug hypersensitivity	54.10	17.87	83	4102	310604	63174233
Gastroenteritis staphylococcal	43.35	17.87	7	4178	73	63484764
Secretion discharge	32.64	17.87	16	4169	12215	63472622
Panic attack	31.11	17.87	19	4166	22312	63462525
Clostridium difficile infection	30.69	17.87	21	4164	29901	63454936
Pulmonary congestion	29.99	17.87	17	4168	17401	63467436
Mucocutaneous candidiasis	29.22	17.87	4	4181	11	63484826
Toxic epidermal necrolysis	28.91	17.87	19	4166	25315	63459522
Biopsy colon abnormal	27.51	17.87	5	4180	109	63484728
Dysbiosis	26.41	17.87	7	4178	899	63483938

Showing 1 to 10 of 27 entries

Previous1 2 3Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Oral pustule	42.57	22.73	8	2002	243	34954678
Psoriatic arthropathy	30.16	22.73	17	1993	19781	34935140
Urticaria	25.31	22.73	24	1986	62353	34892568
Tendon pain	22.90	22.73	8	2002	2987	34951934
Acute generalised exanthematous pustulosis	22.86	22.73	10	2000	6766	34948155

Showing 1 to 5 of 5 entries

Previous1Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Secretion discharge	51.62	17.14	24	5692	14998	79723674
Panic attack	48.89	17.14	27	5689	24189	79714483
Pulmonary congestion	48.71	17.14	28	5688	27072	79711600
Oral pustule	39.90	17.14	8	5708	273	79738399
Toxic epidermal necrolysis	38.22	17.14	29	5687	44552	79694120
Movement disorder	38.19	17.14	24	5692	27235	79711437
Drug hypersensitivity	38.15	17.14	73	5643	298843	79439829
Pulmonary mass	36.81	17.14	24	5692	29010	79709662
Clostridium difficile colitis	34.49	17.14	24	5692	32259	79706413
Acute generalised exanthematous pustulosis	34.17	17.14	19	5697	17235	79721437

Showing 1 to 10 of 32 entries

Previous1 2 3 4Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	J01DD08	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER BETA-LACTAM ANTIBACTERIALS Third-generation cephalosporins
ATC	J01RA15	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE COMBINATIONS OF ANTIBACTERIALS Combinations of antibacterials
ATC	J01RA16	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE COMBINATIONS OF ANTIBACTERIALS Combinations of antibacterials
CHEBI has role	CHEBI:36047	antibacterial drugs
CHEBI has role	CHEBI:88188	allergenic drug
MeSH PA	D000900	Anti-Bacterial Agents
MeSH PA	D000890	Anti-Infective Agents

Showing 1 to 7 of 7 entries

Previous1Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Acute otitis media	indication	3110003
Gonorrhea	indication	15628003	DOID:7551
Haemophilus Influenzae Acute Otitis Media	indication	19021002
Acute gonococcal cervicitis	indication	20943002	DOID:10615
Acute gonococcal urethritis	indication	29864006
Bronchitis	indication	32398004	DOID:6132
Streptococcal tonsillitis	indication	41582007
Upper respiratory infection	indication	54150009
Urinary tract infectious disease	indication	68566005
Tonsillitis	indication	90176007	DOID:10456

Showing 1 to 10 of 28 entries

Previous1 2 3Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	2.45	acidic
pKa2	2.54	acidic
pKa3	3.24	Basic

Orange Book patent data (new drug applications)

Show entries

Search:

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
500MG/5ML	SUPRAX	LUPIN LTD	N202091	Feb. 20, 2013	RX	FOR SUSPENSION	ORAL	9233112	Dec. 14, 2028	METHODS FOR TREATING BACTERIAL INFECTIONS

Showing 1 to 1 of 1 entries

Previous1Next

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
D(2) dopamine receptor	GPCR	P14416	DRD2_HUMAN		IC50	4.24	WOMBAT-PK
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1	Enzyme	P19174	PLCG1_HUMAN		IC50	5.92	CHEMBL
Bacterial penicillin-binding protein	Enzyme		PBPA_ECOLI PBPB_ECOLI DACC_ECOLI PBP2_ECOLI FTSI_ECOLI DACA_ECOLI DACB_ECOLI	INHIBITOR			CHEMBL	CHEMBL
Streptokinase A	Enzyme		STRP_STRP1		EC50	7.22	WOMBAT-PK

Showing 1 to 4 of 4 entries

Previous1Next

External reference:

Show entries

Search:

ID	Source
C04	PDB_CHEM_ID
002737	NDDF
10898	IUPHAR_LIGAND_ID
125110-14-7	SECONDARY_CAS_RN
233747	MMSL
25033	RXNORM
387536009	SNOMEDCT_US
4019391	VUID
4019391	VANDF
4374	MMSL

Showing 1 to 10 of 21 entries

Previous1 2 3Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Cefixime	HUMAN PRESCRIPTION DRUG LABEL	1	16714-766	POWDER, FOR SUSPENSION	100 mg	ORAL	ANDA	27 sections
Cefixime	HUMAN PRESCRIPTION DRUG LABEL	1	16714-766	POWDER, FOR SUSPENSION	100 mg	ORAL	ANDA	27 sections
Cefixime	HUMAN PRESCRIPTION DRUG LABEL	1	16714-767	POWDER, FOR SUSPENSION	200 mg	ORAL	ANDA	27 sections
Cefixime	HUMAN PRESCRIPTION DRUG LABEL	1	16714-767	POWDER, FOR SUSPENSION	200 mg	ORAL	ANDA	27 sections
Cefixime	HUMAN PRESCRIPTION DRUG LABEL	1	43598-673	POWDER, FOR SUSPENSION	100 mg	ORAL	ANDA	22 sections
Cefixime	HUMAN PRESCRIPTION DRUG LABEL	1	43598-673	POWDER, FOR SUSPENSION	100 mg	ORAL	ANDA	22 sections
Cefixime	HUMAN PRESCRIPTION DRUG LABEL	1	43598-674	POWDER, FOR SUSPENSION	200 mg	ORAL	ANDA	22 sections
Cefixime	HUMAN PRESCRIPTION DRUG LABEL	1	43598-674	POWDER, FOR SUSPENSION	200 mg	ORAL	ANDA	22 sections
Cefixime	HUMAN PRESCRIPTION DRUG LABEL	1	62250-663	POWDER, FOR SUSPENSION	100 mg	ORAL	ANDA	27 sections
Cefixime	HUMAN PRESCRIPTION DRUG LABEL	1	62250-663	POWDER, FOR SUSPENSION	100 mg	ORAL	ANDA	27 sections

Showing 1 to 10 of 30 entries

Previous1 2 3Next